LXN Hopes To Stay In Charge of Diabetes Control Market With $57.5 Mil. IPO

LXN's agreement to supply Bristol-Myers Squibb with the company's In Charge for expanded indications of the diabetes drug Glucovance will translate into greater sales of the home glucose monitoring system, according to an Oct. 16 initial public offering prospectus filed with the Securities and Exchange Commission.